Wenjie Wang and Yuk-Ching Tse-Dinh* Pages 730 - 740 ( 11 )
Inhibitors targeting human topoisomerase I and topoisomerase II alpha have provided a useful chemotherapy option for the treatment of many patients suffering from a variety of cancers. While the treatment can be effective in many patient cases, use of these human topoisomerase inhibitors is limited by side-effects that can be severe. A strategy of employing the topoisomerase inhibitors in combination with other treatments can potentially sensitize the cancer to increase the therapeutic efficacy and reduce resistance or adverse side effects. The combination strategies reviewed here include inhibitors of DNA repair, epigenetic modifications, signaling modulators and immunotherapy. The ongoing investigations on cellular response to topoisomerase inhibitors and newly initiated clinical trials may lead to adoption of novel cancer therapy regimens that can effectively stop the proliferation of cancer cells while limiting the development of resistance.
Topoisomerase, Irinotecan, Topotecan, Etoposide, Anthracyclines, DNA repair, Cancer therapy.
Department of Chemistry and Biochemistry, Florida International University, Miami, FL, Department of Chemistry and Biochemistry, Florida International University, Miami, FL